News & Progress

Press Releases

February 06, 2019
Palleon Pharmaceuticals Announces Successful Defense of European Patent
November 26, 2018
Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the AACR Special Conference on Tumor Immunology and Immunotherapy
November 08, 2018
Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting
June 21, 2018
Palleon Pharmaceuticals Appoints Lori Hu of Vertex Ventures HC to Board of Directors
December 12, 2017
Palleon Pharmaceuticals Signs Exclusive License Agreement with King’s College London for Intellectual Property Related to Glycoimmune Checkpoints to Treat Cancer
October 04, 2017
Palleon Pharmaceuticals Raises $47.6 million to Develop Glycoimmune Checkpoint Inhibitors, a New Class of Medicines Designed to Overcome Resistance to First-Generation Immuno-Oncology Drugs

Posters & Publications

Publication
Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment
Cancer Immunology Research. April 23, 2019.
Poster
A Novel Therapeutic Modality of Inhibiting the Glyco-Immune Checkpoint Axis to Treat Cancer
American Association for Cancer Research, April 2019, Poster #LB-109
Poster
A Novel Immunomodulatory Strategy of Targeting Glyco-Immune Checkpoints with EAGLE Technology
American Association for Cancer Research, November 2018
Poster
Targeting Tumor Sialylation in Combination with Checkpoint Inhibitors for Cancer Immunotherapy
Society for Immunotherapy of Cancer, November 2018, Poster #676
Poster
A Novel Immunomodulatory Strategy of Targeting Glyco-Immune Checkpoints with EAGLE Technology
Society for Immunotherapy of Cancer, November 2018, Poster #037
Publication
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Journal of Clinical Investigation. August 21, 2018.

Social Media